FVC (% predicted) Change from baseline · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review
Adverse events ‐ pneumonia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: pneumonia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Adverse effects: anaemia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: anaemia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Thrombocytopenia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: thrombocytopenia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Health‐related quality of life (HAQ‐DI) · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review
All‐cause mortality 12‐month · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in all‐cause mortality 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Change in lung function (diffusing capacity of the lung for carbon monoxide (DLCO) % predicted) · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review
Adverse events ‐ pneumonia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: pneumonia 12‐month compared with placebo (low certainty).
1 finding from 1 review
Adverse events: haematuria 12‐month · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide may leads to higher adverse events: haematuria 12‐month compared with placebo (low certainty).
1 finding from 1 review
Health‐related quality of life (HAQ‐DI) · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review
All‐cause mortality 12‐month · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in all‐cause mortality 12‐month compared with placebo (low certainty).
1 finding from 1 review
FVC (% predicted) Change from baseline · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review
Change in lung function (diffusing capacity of the lung for carbon monoxide (DLCO) % predicted) · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review
Adverse effects: leukopenia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide may leads to higher adverse events: leukopenia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Response to treatment (20% improvement)* · patients with neuropsychiatric involvement in systemic lupus erythematosus
It is very uncertain whether cyclophosphamide changes response to treatment (20% improvement)* compared with methylprednisolone (very low certainty).
1 finding from 1 review
Urinary tract infection · patients with neuropsychiatric involvement in systemic lupus erythematosus
It is very uncertain whether cyclophosphamide changes adverse events ‐ Urinary tract infections compared with methylprednisolone (very low certainty).
1 finding from 1 review
Adverse events ‐ Death · patients with neuropsychiatric involvement in systemic lupus erythematosus
It is very uncertain whether cyclophosphamide changes adverse events ‐ Death compared with methylprednisolone (very low certainty).
1 finding from 1 review
SLICC scores (damage index) Scale: from 0 to 48 (lower is better) · patients with neuropsychiatric involvement in systemic lupus erythematosus
1 finding from 1 review
Disease activity · patients with neuropsychiatric involvement in systemic lupus erythematosus
1 finding from 1 review
Prednisone sparing · patients with neuropsychiatric involvement in systemic lupus erythematosus
1 finding from 1 review